Note: All changes are versus the prior-year period unless otherwise stated
Daiichi Sankyo said revenues during the first quarter were boosted by growth from the iron replacement therapy Injectafer, which had been negatively impacted by the spread of COVID-19 last year along with other drugs, as well as gains from global mainstay products Lixiana and Enhertu.
Daiichi Sankyo is maintaining its forecast for the fiscal year ending March 2022 of JPY 50 billion ($455 million) in profit, which represents a decline of 34.1% year-over-year, on revenues of JPY 990 billion ($9 billion), reflecting a gain of 2.9% over the previous fiscal.
The company noted that aside from terminating the nafamostat inhalation formulation, dubbed DS-2319, for the treatment of COVID-19 last month, it has also discontinued development of the anti-ORAI1 antibody DS-2741 in atopic dermatitis.
To read more Top Story articles, click here.